The marketing authorisation is based primarily on six large Phase III trials
Eli Lily has announced that the European Commission (EU) has granted marketing approval to its injectable once-weekly Trulicity treatment for adults with type 2 diabetes.
Trulicity is a GLP-1 receptor agonists. The marketing authorisation is based primarily on six large Phase III trials and in the first five, Trulicity 1.5mg was superior to placebo and four commonly used type 2 diabetes medicines in reducing average blood sugar levels.
The drug can be taken any time of a day, with or without meals, and either by itself or with other treatments for the most common form of diabetes.